[SCHEDULE 14A INFORMATION o Check the appropriate box: o Preliminary Proxy Statement o o Definitive Proxy Statement Definitiveditional Materials o CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): No fee required. o Feemputed on table below per Exchange Act Rules14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies:]
[FORM 10-Q/A Amendment No.1 (Mark One) x For the quarterly period ended September 30, 2011 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q/A of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q/A of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer & Chairman, Chief Accounting Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director]
[China Pharma Holdings, Inc. Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 November 17, 2011 VIA EDGAR Division of Corporation Finance 100 F Street, NE Mail Stop: 3561 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: China Pharma Holdings, Inc. Form 10-K for the Fiscal Year Ended December 31, 2010 Filed March 3, 2011 and Amended]
[China Pharma Holdings, Inc. Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 November 17, 2011 VIA EDGAR Division of Corporation Finance 100 F Street, NE Mail Stop: 3561 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: China Pharma Holdings, Inc. Form 10-K for the Fiscal Year Ended December 31, 2010 Filed March 3, 2011 and Amended]
[TPI Reports First Quarter Fiscal Year 2012 Financial Results CHENGDU, China, Nov. 14, 2011 Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter of Fiscal Year 2012. First quarter fiscal year 2012 ending September 30, 2011] [Tianyin Pharmaceutical, Incorporated First Quarter 2012 Annual Financial Results Conference Call November 14, 2011 Operator: Dr. James Tong: 1 Sales for the quarter ended September 30, 2011 was $17.5 million, a decrease of 20.5% as compared to $22 million for the quarter ended September 30th, 2010. The sales decrease was mainly due to the pricing pressure on our generic pharmaceuticals,] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 14, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. 000-52236 Delaware of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o o Item 7.01. Regulation FD Disclosure Description]
[TPI Reports First Quarter Fiscal Year 2012 Financial Results CHENGDU, China, Nov. 14, 2011 Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter of Fiscal Year 2012. First quarter fiscal year 2012 ending September 30, 2011] [Tianyin Pharmaceutical, Incorporated First Quarter 2012 Annual Financial Results Conference Call November 14, 2011 Operator: Dr. James Tong: 1 Sales for the quarter ended September 30, 2011 was $17.5 million, a decrease of 20.5% as compared to $22 million for the quarter ended September 30th, 2010. The sales decrease was mainly due to the pricing pressure on our generic pharmaceuticals,] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 14, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. 000-52236 Delaware of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o o Item 7.01. Regulation FD Disclosure Description]
[China Pharmas, Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 November 17, 2011 VIA EDGAR Division ofrporation Finance 100 F Street, NE Mail Stop: 3561 Attention:Jim B. Rosenberg, Seniorsistant Chief Accountant Re: China Pharmas, Form 10-K for the Fiscal Year Ended December 31, 2010]
[China Pharmas, Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 November 17, 2011 VIA EDGAR Division ofrporation Finance 100 F Street, NE Mail Stop: 3561 Attention:Jim B. Rosenberg, Seniorsistant Chief Accountant Re: China Pharmas, Form 10-K for the Fiscal Year Ended December 31, 2010]
[LOGO NEWS RELEASE Skystar Bio-Pharmaceutical Announces Revenue of $20.9 Million For Third Quarter Fiscal Year 2011 Revenues up 12.6%; Net Income up 16.2%; EPS of $1.08 Per Basic and Fully Diluted Share XI’AN, CHINA – November 14, 2011 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2011 Highlights · Revenue increases 13% YoY to record $20.9]
[LOGO NEWS RELEASE Skystar Bio-Pharmaceutical Announces Revenue of $20.9 Million For Third Quarter Fiscal Year 2011 Revenues up 12.6%; Net Income up 16.2%; EPS of $1.08 Per Basic and Fully Diluted Share XI’AN, CHINA – November 14, 2011 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2011 Highlights · Revenue increases 13% YoY to record $20.9]
